Skip to main content

IO Biotech, Inc. (IOBT)

NASDAQ: IOBT · IEX Real-Time Price · USD
2.63 (31.80%)
At close: Dec 3, 2021 4:00 PM
-0.27 (-2.48%)
After-hours:Dec 3, 2021 7:59 PM EST
Market Cap287.51M
Revenue (ttm)n/a
Net Income (ttm)-51.52M
Shares Out26.38M
EPS (ttm)-1.95
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close8.27
Day's Range9.55 - 12.58
52-Week Range6.75 - 17.88
Price Targetn/a
Earnings Daten/a

About IOBT

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win technology platform. Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. We believe this represents a paradigm shift in the management of cancer and that our product candidates have the potential to become cornerstones of the treatment regimens of multiple solid tumors. In a single-arm Phase 1/2 clinical t...

IPO DateNov 5, 2021
CEOMai-Britt Zocca, Ph.D.
Stock ExchangeNASDAQ
Ticker SymbolIOBT
Full Company Profile

Financial Performance

Financial Statements


IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purcha...

WILMINGTON, Del., Nov. 09, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the closing of its initial public offering of 8,222,500 shares of its common stock, inc...

3 weeks ago - GlobeNewsWire

IO Biotech, Inc. Announces Pricing of Initial Public Offering

IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the pricing of its initial public...

4 weeks ago - GlobeNewswire

Immuno-oncology biotech IO Biotech files for a $100 million IPO

IO Biotech, a Phase 3-ready biotech developing immunotherapies for melanoma and other cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

1 month ago - Renaissance Capital

IO Biotech IPO Registration Document (S-1)

IO Biotech, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC